Company research
Immunome Inc.
CIK 1472012Updated Nov 2, 2026
SecurityIMNM · NASDAQ · equity
IMNM price & chart
Loading TradingView…
NASDAQ:IMNM on TradingView ↗About the company
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA and an MAA has been validated by the EMA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radioligand therapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 299,377,000Source | 256,898,000Source | 565,384,000Source | 296,290,000Source | 296,215,000Source | 619,792,000Source | 342,693,000Source | 319,754,000Source | 683,188,000Source | 240,241,000Source | 148,540,000Source | 24,046,000Source |
| Property, Plant and Equipment, NetUSD | 11,563,000Source | 7,172,000Source | 17,359,000Source | 11,025,000Source | 6,096,000Source | 17,081,000Source | 10,953,000Source | 4,302,000Source | 14,636,000Source | 10,113,000Source | 2,073,000Source | 681,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 272,639,000Source | 155,568,000Source | 217,706,000Source | 143,876,000Source | 165,332,000Source | 582,693,000Source | 257,613,000Source | 269,723,000Source | 653,482,000Source | 143,351,000Source | 98,679,000Source | 20,323,000Source |
| Assets, CurrentUSD | 279,924,000Source | 244,040,000Source | 538,449,000Source | 277,432,000Source | 284,284,000Source | 594,309,000Source | 323,130,000Source | 313,326,000Source | 660,777,000Source | 221,339,000Source | 144,703,000Source | 22,649,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,285,000Source | 3,910,000Source | 18,453,000Source | 9,396,000Source | 5,931,000Source | 11,616,000Source | 5,807,000Source | 3,620,000Source | 7,295,000Source | 4,036,000Source | 6,561,000Source | 2,326,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,125,000Source | 2,388,000Source | 3,942,000Source | 3,269,000Source | 2,523,000Source | 2,828,000Source | 4,163,000Source | 1,458,000Source | 2,978,000Source | 4,278,000Source | 1,564,000Source | 284,000Source |
| Other Assets, NoncurrentUSD | 4,555,000Source | 3,198,000Source | 5,424,000Source | 4,354,000Source | 3,212,000Source | 5,364,000Source | 4,347,000Source | 568,000Source | 4,587,000Source | 4,411,000Source | 100,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 35,458,000Source | 41,992,000Source | 40,301,000Source | 27,020,000Source | 42,377,000Source | 31,106,000Source | 35,567,000Source | 34,182,000Source | 48,845,000Source | 59,076,000Source | 28,658,000Source | 7,393,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 9,000Source | 6,000Source | 11,000Source | 9,000Source | 6,000Source | 11,000Source | 9,000Source | 6,000Source | 11,000Source | 6,000Source | 4,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 922,174,000Source | 650,351,000Source | 1,380,535,000Source | 870,092,000Source | 642,251,000Source | 1,370,678,000Source | 864,530,000Source | 637,861,000Source | 1,362,496,000Source | 696,872,000Source | 342,663,000Source | 132,653,000Source |
| Retained Earnings (Accumulated Deficit)USD | -658,264,000Source | -435,521,000Source | -855,130,000Source | -600,807,000Source | -388,421,000Source | -782,003,000Source | -557,410,000Source | -352,299,000Source | -728,164,000Source | -515,770,000Source | -222,807,000Source | -116,001,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 70,000Source | -333,000Source | -24,000Source | 2,000Source | — | -3,000Source | 4,000Source | 0Source | 57,000Source | 22,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 263,919,000Source | 214,906,000Source | 525,083,000Source | 269,270,000Source | 253,838,000Source | 588,686,000Source | 307,126,000Source | 285,572,000Source | 634,343,000Source | 181,165,000Source | 119,882,000Source | 16,653,000Source |
| Liabilities and EquityUSD | 299,377,000Source | 256,898,000Source | 565,384,000Source | 296,290,000Source | 296,215,000Source | 619,792,000Source | 342,693,000Source | 319,754,000Source | 683,188,000Source | 240,241,000Source | 148,540,000Source | 24,046,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 31,445,000Source | 39,528,000Source | 35,713,000Source | 22,878,000Source | 39,900,000Source | 27,412,000Source | 30,797,000Source | 30,768,000Source | 44,990,000Source | 54,307,000Source | 21,829,000Source | 7,331,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 257,000Source | 152,000Source | 0Source | — | — | — | — | 0Source | 63,000Source | — | — |
| Accounts Payable, CurrentUSD | 6,147,000Source | 3,518,000Source | 5,996,000Source | 4,660,000Source | 7,047,000Source | 5,534,000Source | 9,126,000Source | 7,179,000Source | 3,339,000Source | 14,189,000Source | 3,311,000Source | 2,400,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,013,000Source | 2,464,000Source | 4,588,000Source | 4,142,000Source | 2,477,000Source | 3,694,000Source | 4,770,000Source | 1,206,000Source | 3,855,000Source | 4,769,000Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 801,000Source | 1,033,000Source | 378,000Source | — |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 1,340,000Source | 62,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -53,839,000Source | -41,640,000Source | -212,394,000Source | -292,963,000Source | -106,806,000Source | -36,896,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 603,000Source | 611,000Source | 2,466,000Source | 1,567,000Source | 457,000Source | 422,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 7,953,000Source | 5,703,000Source | 25,690,000Source | 15,748,000Source | 6,223,000Source | 5,332,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,421,000Source | -3,810,000Source | -9,164,000Source | 9,526,000Source | -608,000Source | -677,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -58,638,000Source | -53,055,000Source | -190,919,000Source | -110,794,000Source | -7,568,000Source | -28,690,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -12,016,000Source | 5,089,000Source | 60,803,000Source | -85,063,000Source | -30,484,000Source | -248,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,002,000Source | 3,665,000Source | 9,685,000Source | 7,173,000Source | 831,000Source | 248,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -135,000Source | 162,228,000Source | 640,357,000Source | 240,529,000Source | 116,408,000Source | 32,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -70,789,000Source | 114,262,000Source | 510,241,000Source | 44,672,000Source | 78,356,000Source | -28,906,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 272,849,000Source | 155,668,000Source | 217,916,000Source | 144,086,000Source | 582,903,000Source | 257,713,000Source | 653,692,000Source | 143,451,000Source | 98,779,000Source | 20,423,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,747,000Source | 4,892,000Source | 8,799,000Source | 5,347,000Source | 7,953,000Source | 5,703,000Source | 25,690,000Source | 15,748,000Source | 6,223,000Source | 5,332,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -79,000Source | 0Source | -896,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 10,945,000Source | 9,526,000Source | 18,250,000Source | 10,042,000Source | 12,950,000Source | 10,690,000Source | 43,768,000Source | 32,955,000Source | 19,657,000Source | 13,629,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -57,457,000Source | -47,100,000Source | -73,127,000Source | -43,397,000Source | -53,839,000Source | -41,640,000Source | -212,394,000Source | -292,963,000Source | -106,806,000Source | -36,896,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -57,457,000Source | -47,100,000Source | -73,127,000Source | -43,397,000Source | -53,839,000Source | -41,640,000Source | -212,394,000Source | -292,963,000Source | -106,806,000Source | -37,518,000Source |
| Operating ExpensesUSD | — | — | 60,138,000Source | 53,432,000Source | 78,135,000Source | 50,493,000Source | 59,331,000Source | 47,562,000Source | 231,054,000Source | 314,841,000Source | 123,548,000Source | 36,901,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 5,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 45,897,000Source | 20,000,000Source | 34,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 0Source | 15,000,000Source | 200,000,000Source | 155,000,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 229,000Source | 213,000Source | 913,000Source | 2,024,000Source | 371,000Source | 32,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 2,910,000Source | 0Source | 4,015,000Source | 0Source | 2,926,000Source | 6,941,000Source | 9,041,000Source | 14,018,000Source | — |
| Operating Income (Loss)USD | — | — | -60,138,000Source | -50,522,000Source | -78,135,000Source | -46,478,000Source | -59,331,000Source | -44,636,000Source | -224,113,000Source | -305,800,000Source | -109,530,000Source | -36,901,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 5,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -57,457,000Source | -47,100,000Source | -73,127,000Source | -43,397,000Source | -53,839,000Source | -41,640,000Source | -212,394,000Source | -292,963,000Source | -106,806,000Source | -36,896,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.65Source | -0.78Source | -0.65Source | -0.5Source | -0.48Source | -0.52Source | -2.43Source | -5Source | -5.38Source | -3.09Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.65Source | -0.78Source | -0.65Source | -0.5Source | -0.48Source | -0.52Source | -2.43Source | -5Source | -5.38Source | -3.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 87,957,868Source | 60,205,327Source | 113,272,931Source | 87,010,742Source | 113,136,836Source | 79,410,354Source | 87,350,956Source | 58,639,441Source | 19,843,651Source | 12,126,573Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 87,957,868Source | 60,205,327Source | 113,272,931Source | 87,010,742Source | 113,136,836Source | 79,410,354Source | 87,350,956Source | 58,639,441Source | 19,843,651Source | 12,126,573Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 10,945,000Source | 9,526,000Source | 18,250,000Source | 10,042,000Source | 12,950,000Source | 10,690,000Source | 43,768,000Source | 32,955,000Source | 19,657,000Source | 13,629,000Source |
| Interest Income (Expense), NetUSD | — | — | 2,681,000Source | 3,422,000Source | 5,008,000Source | 3,081,000Source | 5,492,000Source | 2,996,000Source | 11,719,000Source | 12,837,000Source | 2,724,000Source | 5,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -57,457,000Source | -47,100,000Source | -73,127,000Source | -43,397,000Source | -53,839,000Source | -41,640,000Source | -212,394,000Source | -292,963,000Source | -106,806,000Source | -37,518,000Source |
| Operating ExpensesUSD | — | — | 60,138,000Source | 53,432,000Source | 78,135,000Source | 50,493,000Source | 59,331,000Source | 47,562,000Source | 231,054,000Source | 314,841,000Source | 123,548,000Source | 36,901,000Source |
| Research and Development ExpenseUSD | — | — | 49,193,000Source | 37,200,000Source | 59,885,000Source | 40,451,000Source | 46,381,000Source | 36,872,000Source | 177,286,000Source | 129,542,000Source | 23,089,000Source | 23,272,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | 622,000Source |
Offerings
Registration 333-299933
Registration 333-299934
Filing attachments
d137036dex410.htm · S-3ASR · 2026-11-09
Exhibit 4.10 I MMUNOME, I NC. AND _____________, A S W ARRANT A GENT F ORM OF C OMMON S TOCK W ARRANT A GREEMENT D ATED A S O F __________ I MMUNOME, I NC. F ORM OF C OMMON S TOCK W ARRANT A GREEMENT T HIS C OMMON S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between I MMUNOME, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as …
Read attachment ↗d137036dex411.htm · S-3ASR · 2026-11-09
Exhibit 4.11 I MMUNOME, I NC. AND _____________, A S W ARRANT A GENT F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT D ATED A S O F __________ I MMUNOME, I NC. F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT T HIS P REFERRED S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between I MMUNOME, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in…
Read attachment ↗d137036dex412.htm · S-3ASR · 2026-11-09
Exhibit 4.12 I MMUNOME, I NC. AND _____________, A S W ARRANT A GENT F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT D ATED A S O F __________ I MMUNOME, I NC. F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT T HIS D EBT S ECURITIES W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between I MMUNOME, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in…
Read attachment ↗d137036dex47.htm · S-3ASR · 2026-11-09
Exhibit 4.7 IMMUNOME, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗imnm-ex99_1.htm · 10-Q · 2026-11-09
Exhibit 99.1 EXPLANATORY NOTE Immunome, Inc. (the “Company”) is filing this Exhibit 99.1 to the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2026 solely to recast certain segment financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, originally filed with the Securities and Exchange Commission (“the SEC”) on March 3, 2026 (the “2025 Form 10-K”). The recast information reflects change…
Read attachment ↗imnm-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update November 9, 2026 • Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA) • Initial IM-1021 results show objective responses across all dose levels evaluated in B-cell non-Hodgkin lymphoma; updated Phase 1 dataset expected at ASH on December 14 • Investigational New Drug (IND) clearance received for IM-13…
Read attachment ↗